IMUNOR® Preparation in the Prevention of COVID-19

• Status: Completed
• Trial end date: 2021-06-02
• Target enrollment: 0
• Participant gender: All

Summary

The aim of the study is to achieve prevention of COVID-19 disease in healthcare professionals with the administration of the IMUNOR® preparation, and decreasing the symptoms should the disease appear.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University Hospital Ostrava

Criteria

Inclusion Criteria:

• Study subjects 18-60 years old

• Ability to cooperate upon the study and to give informed consent

Exclusion Criteria:

• Use of any other immunomodulation treatment one month prior to enrolment and in the course of the study

• Acute disease of the cardiovascular, urogenital, respiratory or nervous system